Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.
Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. · 2010
Read Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. by Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2939781.txt.
Introduction
Okusaka and colleagues compared two chemotherapy plans for advanced bile duct cancer in Japanese patients in a 2010 multicentre study. A British trial had hinted that pairing gemcitabine with cisplatin beat gemcitabine on its own.
Eighty-four patients were assigned by chance to the pair or to gemcitabine alone, given in repeating cycles for up to nearly a year. The pair produced modestly longer survival, longer time before the cancer grew, and more tumour shrinkage. Low blood cell counts were the commonest severe side effects, occurring more often with the pairing. The authors judged the pair tolerable and fit as a standard option.
Catalog record
| CREATOR | Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan By T Okusaka, K Nakachi, A Fukutomi, N Mizuno, S Ohkawa, A Funakoshi, M Nagino, S Kondo, S Nagaoka, J Funai, M Koshiji, Y Nambu Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6605779 ABSTRACT Background: A British randomised study of gemcitabine plus cisplatin (GC) combination showed promising results in biliary tract cancer (BTC) patients. In our study, we evaluated the efficacy and safety of this combination compared with gemcitabine alone (G) in Japanese BTC patients. Methods: Overall, 84 advanced BTC patients were randomised to either cisplatin 25 mg m−2 plus gemcitabine 1000 mg m−2 on days 1, 8 of a 21-day cycle (GC-arm), or single-agent gemcitabine 1000 mg m−2 on days 1, 8 and 15 of a 28-day cycle (G-arm). Treatments were repeated for at least 12 weeks until disease progression or unacceptable toxicity occurred, up to a maximum of 48 weeks. Results: A total of 83 patients were included in the analysis. For the GC and G-arms, respectively, the 1-year survival rate was 39.0 vs 31.0%, median survival time 11.2 vs 7.7 months, median progression-free survival time 5.8 vs 3.7 months and overall response rate 19.5 vs 11.9%. The most common grade 3 or 4 toxicities (GC-arm/G-arm) were neutropenia (56.1%/38.1%), thrombocytopenia (39.0%/7.1%), leukopenia (29.3%/19.0%), haemoglobin decrease (36.6%/16.7%) and γ-GTP increase (29.3%/35.7%). Conclusions: Gemcitabine plus cisplatin combination therapy was found to be effective and well tolerated, suggesting that it could also be a standard regimen for Japanese patients. Although biliary tract cancer (BTC) is a rare type of cancer throughout the world, it is more prevalent in East Asia and Latin America than in other countries (Matsuda and Marugame, 2007; Randi et al, 2009). According to ‘Demographic Statistics in Japan (2009)’ (compiled by the Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour, and Welfare (MHLW)), the number of deaths due to BTC was 17 311 in 2007, making this cancer the sixth leading cause of cancer death in Japan. Despite great progress in diagnostic imaging, most cases of BTC are diagnosed as advanced and inoperable. Even if the tumour is not locally advanced, the primary tumour site is often contiguous with vital organs such as the liver, pancreas, or duodenum, or with major vessels such as the portal vein or hepatic artery. This anatomical peculiarity precludes resection of tumours in many cases. Furthermore, even if curative-intent surgical resection is performed, the cancer often relapses due to its invasive nature and its anatomical characteristics. Systemic chemotherapy is usually indicated for patients with unresectable, advanced BTC or for those who have relapsed after operation; however, no standard treatment has yet been established for such patients. Gemcitabine hydrochloride is a deoxycytidine derivative that inhibits DNA elongation through intracellular phosphorylation of ribonucleotide reductase. In Japan, a single-arm Phase II study in patients with unresectable BTC confirmed that gemcitabine monotherapy had moderate efficacy and manageable toxicity, both of which were comparable with approved treatments for other cancers (Okusaka et al, 2006). As gemcitabine had also been found to exhibit synergistic effects on cytotoxic activity in vitro and in vivo when combined with cisplatin (Peters et al, 1995; Bergman et al, 1996), clinical studies were conducted in various cancers with this combination. Results from these studies eventually led to use of the gemcitabine plus cisplatin (GC) combination as one of the standard treatments for non-small cell lung cancer and bladder cancer. The combination of GC has also been studied by many researchers for the treatment of BTC (Park et al, 2006; Eckel and Schmid, 2007; Pasetto et al, 2007; Lee et al, 2008). So far, the largest randomised Phase III study has been the recent UK ABC-02 study, in which the efficacy and safety of gemcitabine 1000 mg m−2 alone vs the combination of gemcitabine 1000 mg m−2 plus cisplatin 25 mg m−2 was evaluated by British research groups (Cancer Research UK and University College London). That study was initiated as a randomised phase II study with gemcitabine alone vs GC (UK ABC-01 study) and then was expanded to a phase III study (ABC-02 study) (Valle et al, 2009a, 2009b). Our study was planned to follow-up on an earlier study of gemcitabine monotherapy conducted in Japanese BTC patients (Okusaka et al, 2006). Given the encouraging results from the UK ABC-01 study, we conducted this study to (1) evaluate both gemcitabine monotherapy and the GC combination in Japanese BTC patients, and (2) determine whether benefits similar to those observed in the UK study could be obtained for the combination regimen. The primary objective of the study was to compare the 1-year survival rate in patients with BTC who received one of these two therapies. The secondary objectives included response rate, progression-free survival (PFS) and assessment of safety. MATERIALS AND METHODS Study design This was a multicentre, randomised phase II study to evaluate the efficacy and safety of GC combination compared with single-agent gemcitabine in chemotherapy-naive patients with locally advanced or metastatic BTC. Patients were randomised to either single-agent gemcitabine 1000 mg m−2 on days 1, 8 and 15 of a 28-day cycle (G-arm) or cisplatin 25 mg m−2 followed by gemcitabine 1000 mg m−2 on days 1, 8 of a 21-day cycle (GC-arm). Randomisation was stratified by primary site (gallbladder cancer or other BTC) and the presence or absence of primary tumour. Eligibility criteria Eligible patients met the following criteria: histologically confirmed unresectable locally advanced or metastatic cancer of the biliary tract; no history of earlier chemotherapy; performance status of 0 or 1; a life expectancy of at least 3 months; at least 20 years of age at the time of study entry; adequate function of major organs (haemoglobin ⩾10 g per 100 ml, white blood cells ⩾3000/mm3, neutrophils ⩾1500/mm3, platelets ⩾100 000/mm3, AST/ALT/ALP ⩽3 times upper limit of normal (ULN), total bilirubin ⩽2 times ULN, ⩽3 times ULN for patients with obstructive jaundice or metastases to the liver, serum creatinine ⩽1.5 times ULN, creatinine clearance or 24-h creatinine clearance ⩾45 ml min−1). This study followed the ethical principles that have their origins in the Declaration of Helsinki, and was conducted in accordance with the protocol, the ‘ordinance on Good Clinical Practice’ and related regulations. Written informed consent was obtained from all patients who were considered eligible for participation in this study before enrolment. The Efficacy and Safety Evaluation Committee, an independent review board, was consulted if any efficacy and safety issues arose in the study. Study treatment The assigned treatment was given for a minimum of 12 weeks (at least four cycles in the GC-arm and three cycles in the G-arm) and continued to a maximum of 48 weeks (up to 16 cycles in the GC-arm and up to 12 cycles in the G-arm), unless disease progression (PD) was evident, an intolerable adverse event occurred or the patient was required to withdraw from the study. Efficacy and safety assessment All patients who received at least 1 dose of the study drug were included in the efficacy and safety assessment. Response rate was evaluated according to the Response Evaluation Criteria in Solid Tumors. Evaluation of tumours after patient randomisation was performed every 6 weeks until PD.